Xeris Pharmaceuticals Inc (XERS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.04B
Last updated: Nov 17, 2026 at 11:06 AM ET
Xeris Pharmaceuticals Inc (XERS) Financials: Revenue, Profit and Cash Flow
Xeris Pharmaceuticals reported revenue of $291.85M for the fiscal year ended Dec 31, 2025, up 43.7% from the year before. That year, net income was $554.00K with a net margin of 0.2%, operating cash flow was $28.63M and free cash flow was $27.93M. The quarter ended Sep 30, 2026 had revenue of $107.22M and net income of $11.29M.
Revenue and Margins
The operating margin was 8.5% in the fiscal year ended Dec 2025, the highest of the 4 years shown with an operating margin. Over the 9 years to Dec 2025, revenue grew from $1.07M, a compound annual rate of 86.5%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $291.85M | +43.7% | 85.4% | 8.5% | 0.2% |
| Dec 2024 | $203.07M | +23.9% | 81.9% | -16.6% | -27.0% |
| Dec 2023 | $163.91M | +48.7% | 82.5% | -26.8% | -38.0% |
| Dec 2022 | $110.25M | +122.3% | 79.5% | -74.3% | -85.9% |
| Dec 2021 | $49.59M | +146.0% | 73.1% | -232.2% | -247.5% |
| Dec 2020 | $20.16M | +640.4% | 55.1% | -414.5% | -452.2% |
| Dec 2019 | $2.72M | +10.4% | 41.1% | -4496.0% | -4613.5% |
| Dec 2018 | $2.46M | +58.4% | 98.3% | -2407.5% | -2437.3% |
| Dec 2017 | $1.56M | +44.7% | 99.7% | -1711.4% | -1706.6% |
| Dec 2016 | $1.07M | N/A | 99.3% | -1230.8% | -1228.7% |
Income Statement
In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, net income rose 1718.0% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $291.85M | $203.07M | $163.91M | $110.25M | $49.59M | $20.16M | $2.72M | $2.46M | $1.56M | $1.07M |
| Cost of revenue | $42.57M | $36.83M | $28.64M | $22.63M | $13.32M | $9.05M | $1.60M | $42.00K | $4.00K | $8.00K |
| Gross profit | $249.28M | $166.24M | $135.27M | $87.61M | $36.27M | $11.11M | $1.12M | $2.42M | $1.55M | $1.07M |
| Research and development | $31.16M | $25.56M | $22.34M | $20.97M | $25.16M | $20.92M | $60.44M | $40.65M | $20.17M | $10.24M |
| Operating income | $24.90M | -$33.65M | -$44.01M | -$81.94M | -$115.16M | -$83.55M | -$122.38M | -$59.34M | -$26.63M | -$13.23M |
| Net income | $554.00K | -$54.84M | -$62.26M | -$94.66M | -$122.72M | -$91.14M | -$125.58M | -$60.08M | -$26.55M | -$13.21M |
| EBITDA | $40.96M | -$14.37M | -$24.71M | -$68.93M | -$112.61M | -$81.02M | -$119.57M | -$57.22M | -$26.38M | -$13.09M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $107.22M | $92.10M | $83.13M | $85.81M | $74.38M | $71.54M | $60.12M | $60.10M | $54.27M | $48.06M | $40.64M | $44.39M |
| Gross profit | $94.80M | $79.59M | $72.55M | $74.86M | $63.38M | $59.64M | $51.39M | $50.62M | $40.67M | $40.27M | $34.67M | $29.27M |
| Operating income | $16.92M | $5.17M | $7.92M | $16.77M | $6.73M | $4.48M | -$3.09M | $1.68M | -$12.89M | -$8.19M | -$14.24M | -$9.84M |
| Net income | $11.29M | -$31.10M | $2.23M | $11.08M | $621.00K | -$1.93M | -$9.22M | -$5.11M | -$15.74M | -$15.01M | -$18.98M | -$13.39M |
Balance Sheet
As of Dec 2025, total debt of $220.34M exceeded cash and equivalents by $109.29M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $383.53M | $323.06M | $322.60M | $344.52M | $304.36M | $159.15M | $108.99M | $120.03M | $45.00M | $33.53M |
| Current assets | $240.31M | $167.66M | $156.26M | $186.82M | $142.60M | $152.21M | $87.48M | $117.90M | $44.05M | $33.17M |
| Cash and equivalents | $111.04M | $71.62M | $67.45M | $121.97M | $67.27M | $37.60M | $19.52M | $45.72M | $42.05M | $32.27M |
| Total liabilities | $369.84M | $352.68M | $329.38M | $299.33M | $209.13M | $125.39M | $94.55M | $44.62M | $102.83M | $65.47M |
| Short-term debt | $0 | $15.10M | $19.11M | $0 | $1.58M | N/A | N/A | $8.21M | $2.56M | $902.00K |
| Long-term debt | $220.34M | $217.01M | $190.93M | $187.07M | $88.07M | $87.02M | $58.30M | $31.89M | N/A | N/A |
| Shareholder equity | $13.69M | -$29.61M | -$6.78M | $45.19M | $95.23M | $33.76M | $14.44M | $75.41M | -$57.83M | -$31.93M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $423.22M | $411.90M | $392.01M | $383.53M | $370.19M | $334.69M | $315.45M | $323.06M | $321.10M | $331.73M | $336.62M | $322.60M |
| Total liabilities | $374.44M | $421.64M | $379.00M | $369.84M | $371.05M | $353.99M | $350.58M | $352.68M | $349.43M | $351.02M | $345.79M | $329.38M |
| Cash and equivalents | $131.08M | $121.75M | $111.75M | $111.04M | $91.60M | $59.28M | $58.44M | $71.62M | $59.23M | $57.60M | $62.69M | $67.45M |
| Shareholder equity | $48.78M | -$9.73M | $13.01M | $13.69M | -$861.00K | -$19.30M | -$35.13M | -$29.61M | -$28.32M | -$19.29M | -$9.18M | -$6.78M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 97.6% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $28.63M | -$36.98M | -$47.02M | -$102.89M | -$95.53M | -$80.56M | -$104.35M | -$56.28M | -$24.66M | -$16.09M |
| Capital expenditures | $696.00K | $868.00K | $2.26M | $524.00K | $1.08M | $377.00K | $1.11M | $1.51M | $700.00K | $35.00K |
| Free cash flow | $27.93M | -$37.85M | -$49.29M | -$103.42M | -$96.62M | -$80.94M | -$105.45M | -$57.79M | -$25.36M | -$16.12M |
| Dividends paid | N/A | N/A | N/A | $147.05M | $25.09M | $95.64M | $60.68M | N/A | N/A | N/A |
| Share repurchases | N/A | N/A | N/A | N/A | $54.00K | $4.32M | N/A | N/A | N/A | N/A |
| Investing cash flow | -$696.00K | $4.88M | -$6.00M | $34.46M | $97.96M | -$27.41M | -$2.38M | -$68.26M | -$700.00K | -$35.00K |
| Financing cash flow | $11.39M | $36.17M | -$1.61M | $127.47M | $27.25M | $126.06M | $80.53M | $128.21M | $35.14M | $3.90M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $35.47M | $8.26M | $9.87M | $20.04M | $18.43M | $182.00K | -$10.03M | $1.98M | -$8.30M | -$10.35M | -$20.30M | $7.47M |
| Capital expenditures | N/A | $209.00K | $325.00K | $333.00K | $71.00K | $279.00K | $13.00K | $220.00K | $87.00K | $397.00K | $164.00K | $132.00K |
| Free cash flow | N/A | $8.05M | $9.54M | $19.71M | $18.36M | -$97.00K | -$10.04M | $1.75M | -$8.39M | -$10.74M | -$20.47M | $7.34M |
Frequently Asked Questions About XERS
What is Xeris Pharmaceuticals' annual revenue?
Xeris Pharmaceuticals reported revenue of $291.85M for the fiscal year ended Dec 31, 2025.
How fast is Xeris Pharmaceuticals' revenue growing?
Revenue was up 43.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 38.3%.
Is Xeris Pharmaceuticals profitable?
Yes. Xeris Pharmaceuticals reported net income of $554.00K for the fiscal year ended Dec 31, 2025, with a net margin of 0.2%.
How much free cash flow does XERS generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $28.63M minus capital expenditures of $696.00K produced free cash flow of $27.93M.
How much debt does Xeris Pharmaceuticals have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $220.34M, short-term debt of $0 and cash and equivalents of $111.04M.
XERS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors